Preclinical News and Research

RSS

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus Biotherapeutics today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the innate immune system.

20 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

Researchers report increasing disparities between resource inputs, outcomes in biomedical research

As more money has been spent on biomedical research in the United States over the past 50 years, there has been diminished return on investment in terms of life expectancy gains and new drug approvals, two Johns Hopkins Bloomberg School of Public Health researchers say.

18 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

GlySens secures FDA approval to extend current human clinical evaluation of fully implanted CGM system

GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.

17 Aug 2015

Bionik Laboratories reports net loss for second quarter 2015

Bionik Laboratories Corp., a pioneering medical device and robotics company developing technologies and solutions for individuals with neurological disorders, announced today its financial results for the quarter ended June 30, 2015.

17 Aug 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.

12 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

Next generation quantitative live-cell microscope released by Bruker

Bruker today announced the release of the Opterra II™ Multipoint Scanning Confocal Microscope, which represents the next generation of quantitative live-cell microscopes.

From Bruker 11 Aug 2015

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

AXT is proud to announce that they have just signed an exclusive distributorship agreement with US-based Endra Life Sciences. Endra are a developer of photoacoustic (PA) technology for bio-medical imaging and have commercialised their breakthrough technology. This new deal further bolsters AXT’s life science and preclinical imaging portfolios with another unique technology.

From MR Solutions 11 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

7 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

5 Aug 2015

Imperial Innovations announces launch of pre-clinical spinout company, Orthonika

Imperial Innovations is pleased to announce the launch of Orthonika, a spinout company from Imperial College London that is developing a novel knee meniscus replacement, MenisciKnit.

4 Aug 2015

Prokarium receives funding to complete pre-clinical development of new Chlamydia vaccine

Prokarium Ltd, a biotechnology company developing transformational oral vaccines, today announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.

4 Aug 2015

Preclinical News and Research

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Researchers report increasing disparities between resource inputs, outcomes in biomedical research

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

GlySens secures FDA approval to extend current human clinical evaluation of fully implanted CGM system

Bionik Laboratories reports net loss for second quarter 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

Ardelyx reports net income of $9.0 million for second quarter 2015

Next generation quantitative live-cell microscope released by Bruker

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Imperial Innovations announces launch of pre-clinical spinout company, Orthonika

Prokarium receives funding to complete pre-clinical development of new Chlamydia vaccine

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics